Table 3.
Flow cytometric analysis of the effect of RLPLGA Nanoparticles on LNCaP prostate cancer cell lines at 48 h.
| Concentration (µM) | Resveratrol (RL) |
RLPLGA |
||||
|---|---|---|---|---|---|---|
| G0-G1 | S | G2-M | G0-G1 | S | G2-M | |
| 0 | 49.3% | 22.1% | 25.5% | 48.6% | 19.3% | 30.9% |
| 10 | 56.0% | 19.9% | 24.7% | 58.8% | 22.1% | 19.0% |
| 20 | 61.1% | 20.6% | 14.5% | 69.7% | 14.4% | 11.2% |
| 30 | 68.3% | 26.0% | 4.7% | 71.2% | 24.6% | 3.1% |
| 40 | 71.8% | 24.0% | 2.6% | 79.1% | 16.3% | 0.0% |
| 50 | 83.0% | 16.2% | 0.0% | 90.4% | 7.6% | 0.0% |
RLPLGA Nanoparticles arrested cells in G1-S phase transition in prostate cancer cells. LNCaP prostate cancer cell lines untreated and treated with (0–50 µM) RLPLGA Nanoparticles or Resveratrol for 48 h. The cells were then harvested, fixed in ethanol, stained with propidium iodide, and analyzed by FACS.